24th Sep 2015 07:12
LONDON (Alliance News) - GlaxoSmithKline PLC said Thursday that it plans to file a supplemental new drug application for its Relvar Ellipta treatment for chronic obstructive pulmonary disease in Japan during the first quarter of 2016.
The pharmaceutical giant said this decision follows results from a phase III efficacy and safety study involved 1,620 patients, including 370 from Japan, which showed that patients who received the Relvar Ellipta combination achieved a "statistically significant improvement in lung function".
The full results from the study will be the subject of a future publication or presentation, the company said.
Shares in GlaxoSmithKline were flat at 1,273.00 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline